Founded on March 28, 1995 with a vision of creating a healthier China, the company has rapidly evolved from a distributor of pharmaceutical products into a leading manufacturer and supplier of drugs in the rapidly growing China pharmaceutical market. They currently have three Good Manufacturing Practices("GMP")-certified modernized manufacturing bases, two nationwide sales and marketing subsidiaries, one research and development center and total of more than 1,800 employees.
They currently manufacture and sell 35 pharmaceutical products and are the exclusive distributor of three additional pharmaceutical products marketed under brand name, covering a wide range of diseases such as cancer, cerebrovascular and cardiovascular diseases, infections, arthritis, diarrhea, allergies, respiratory conditions and urinary conditions. Their market leading pharmaceutical products include an anti-stroke medication, Bicun, the first synthetic free radical scavenger (edaravone injection) sold in China; Zailin, a generic amoxicillin granule antibiotic; an innovative anti-cancer medication, Endu (also known as “Endostar”), the first recombinant human endostatin injection approved for sale in China; Yingtaiqing, a generic diclofenac sodium sustained-release capsule for inflammation and pain relief; Anqi, a generic amoxicillin with clavulanate potassium antibiotic; and Biqi, an OTC generic smectite powder for diarrhea. These products contributed annual revenue of more than RMB 800 million in 2006. In addition to these core products, Simcere Kechuanning, Zaike, and Faneng each contributed annual revenue of RMB 30 - 40 million in 2006. In addition, China’s State Food and Drug Administration ("SFDA") has also granted their approval for the manufacture and sale of 100 other products.
Their strategic focus is to introduce first-to-market generic and innovative pharmaceuticals for the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy, such as their first-to-market generic anti-stroke medication Bicun and their anti-cancer medication Endu (also known as “Endostar”).
In September 2006, Simcere acquired 80% of Shandong Simcere Medgenn Bio-Pharmaceutical Co., Ltd for RMB 200 million and launched its new patented anti-cancer drug, Endu (also known as "Endostar"), the first recombinant human endostatin successfully commercialized in the world. This purchase was one of the biggest acquisition cases in China’s pharmaceutical industry targeting a single pharmaceutical product’s intellectual property. The successful commercialization of Endu is a result of joint efforts from their R&D team, led by Dr. Yongzhang Luo, the independent clinical research team, headed by Dr. Yan Sun, and our professional sales and marketing team. Clinical research was conducted in 24 hospitals in China and an independent specialists committee audited the clinical research statistics and data. The results of their Phase III clinical trial on 493 non-small-cell lung cancer ("NSCLC") patients showed that the Endu-plus-chemotherapy approach provides an effective alternative for treating NSCLC.
Their goal is to become a leading pharmaceutical company by providing innovative medicine in China. They believe constant innovation in research and development is vital to their long-term competitiveness and success and will determine the future of the pharmaceutical industry in China. They will maintain their commitment to investing in research and development activities while focusing on innovative products with a high potential for commercialization, as well as first-to-market generic pharmaceutical products. Their over 5,000m2 research and development center in Nanjing provides a solid platform to support a variety of research activities including synthetic research, drug analysis and pharmacological and cytological research. Their post-doctorate research workstation currently has four research staff and it was certified by the State Ministry of Human Resources. To supplement their in-house research and development capabilities, their also plan to increase their collaborations with domestic and international pharmaceutical and biotechnology companies and institutions. Their agreement with Tsinghua University in February 2006 established a Joint Laboratory for Drug Discovery to engage in the research and development of innovative pharmaceuticals. Simcere’s commitment to research and development helps to ensure a robust pipeline of product candidates in various stages of development, including products for the treatment of cancer, cerebrovascular diseases, infections, rheumatoid arthritis, nasal allergies and nausea and vomiting associated with chemotherapy. With their deep knowledge about the Chinese pharmaceutical market and increasing cooperation with domestic and international resources.
Mr. Jinsheng Ren
Founder, Chairman, and Chief Executive OfficerMr. Ren is Simcere’s founder, chairman of our board of directors and our chief executive officer. Prior to founding Simcere in March 1995, he was a department manager at Jiangsu Pharmaceutical Industries Co., Ltd. From 1982 to 1992, he was the vice general manager of Qidong Gaitianli Medicines Co., Ltd. Mr. Ren graduated from the Nanjing University of Traditional Chinese Medicine in 1982 majoring in Chinese Medicine, and received a master’s degree in Economics from University of Macquarie in Australia in 2003. He is currently a guest professor at the Nanjing University of Traditional Chinese Medicine and an adjunct professor of Northwest University in China.
Mr. Xiaojin Yin
Vice President of Research and Development Mr. Xiaojin Yin is Simcere’s Vice President in charge of research and development of our company. From 2003 to 2006, Mr. Yin was the general manager of Jiangsu Simcere Pharmaceutical R&D Co., Ltd., or Simcere Research. From 2000 to 2003, he was the general manager assistant of both Simcere Pharmaceutical Co., Ltd. and a manager of Simcere Research. From 1992 to 2000, he was the head of the medical research department of the China Pharmaceutical University in Nanjing. From 1991 to 1992, Mr. Yin was the general manager of the medicine production facility at China Pharmaceutical University. Mr. Yin received a bachelor’s degree in Medical Sciences from China Pharmaceutical University in 1982 and a master’s degree in Industrial Engineering from the Nanjing University of Science and Technology in 2001.
Mr. Jindong Zhou
Vice President of Manufacturing Jindong Zhou is a Vice President in charge of manufacturing of our company and has worked in our company since 1996. From 2001 to 2006, Mr. Zhou was the general manager of Simcere Pharmaceuticals Co., Ltd. From 2000 to 2001, he was the deputy general manager of Jiangsu Simcere Pharmaceuticals Co., Ltd. Mr. Zhou graduated from the Nanjing University of Traditional Chinese Medicine majoring in Chinese Medicine in 1982 and has been studying toward an MBA degree at the Nanjing Normal University’s School of Management since 2005.
Dr. Hiu Ming Pang
Senior Assistant to the Chief Executive Officer Dr. Hiu Ming Pang is the Senior Assistant to the Chief Executive Officer responsible for technology transfer and international business development. Since 2000, Dr. Pang has been and continues to be a director of the Life Sciences Advisory Group. From 1998 to 2000, he was executive director of Asia Healthcare, Inc. From 1993 to 1999, he was chairman and chief executive officer of Baker Norton Asia. From 1982 to 1988, Dr. Pang was the China project manager for Glaxo Wellcome UK. Dr. Pang is a member of the Royal Pharmaceutical Society of Great Britain, a member of the Institute of Chemical Engineers of Great Britain, and a fellow member and proposed council member of the Hong Kong Biotechnology Association. Dr. Pang received a bachelor’s degree in Pharmacy from the University of London in 1977, a Ph.D. in Pharmaceutical Engineering from the University of London in 1981, and a postgraduate diploma in Management Studies from Ealing College in London in 1986.
Research and Development
At Simcere, R&D is at the core of their commitment to developing first-to-market generic and innovative new pharmaceutical products, especially to treat diseases with a high incidence and/or mortality rate which demand more effective pharmacotherapy, such as cancer, cerebrovascular diseases, strokes, rheumatoid arthritis and infectious diseases.
Their approach is to balance their efforts between the development of first-to-market generic pharmaceuticals and innovative pharmaceuticals. Before beginning any R&D project, they perform a thorough market analysis to assess a potential drug’s commercial viability and, in the case of generic pharmaceuticals, to determine its first-to-market status.
Beyond the development of new pharmaceutical products, they are continually working to enhance their existing portfolio by making them safer with fewer side effects, more convenient to administer and more effective.
They currently have 78 research staff, 32 of which hold master’s degrees and 14 of which hold Ph.D. degrees. Located primarily at their R&D facilities center in Nanjing, their R&D team has access to several technology platforms and is capable of conducting research on both chemical pharmaceuticals and biopharmaceuticals.
Ensuring Leadership for Future Innovation
Simcere Postdoctoral Research ProgramIn 2003, with the goal of pursuing innovation and establishing ongoing leadership in China’s pharmaceutical industry, Simcere established an innovative postdoctoral research program to offer post-doctoral researchers the opportunity to conduct innovative research and development projects through our facility in Nanjing under the guidance of their internal and external research scientists. They currently have 4 post-doctoral researchers participating in this program.
Collaboration in Research
Beyond in-house research and development efforts, Simcere pursues active collaboration with leading universities and research institutions both within China and abroad.
Currently, they have established a Joint Laboratory for Drug Discovery with Tsinghua University for product research and development and have ongoing research projects with other leading universities and institutions including the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences.
They plan to continue to increase collaborations with international pharmaceutical and biotechnology companies to develop and market new pharmaceutical products in China, particularly in the anti-cancer or the cardiovascular and cerebrovascular field. Looking forward, they believe international collaboration will help them to gain valuable know-how and experience, further strengthen their research and development capabilities, and expand their product portfolio and pipeline.